Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Thursday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 4.4 %

NYSE:BTX opened at $6.68 on Thursday. The stock’s fifty day moving average is $1.88 and its two-hundred day moving average is $1.31. Brooklyn ImmunoTherapeutics has a 52 week low of $6.66 and a 52 week high of $8.31. The stock has a market capitalization of $392.96 million, a price-to-earnings ratio of -2.94 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Dividend Announcement

The company also recently declared a monthly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, March 14th will be paid a dividend of $0.0862 per share. This represents a $1.03 dividend on an annualized basis and a yield of 15.48%. The ex-dividend date is Friday, March 14th. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is -40.09%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.